Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion

Eton Pharmaceuticals

14/05/2026 21:17

Overview

US rare disease drugmaker's Q1 product sales grew 73% yr/yr, driven by portfolio expansion

Company raised 2026 revenue guidance to exceed $120 mln, citing strong year-to-date performance

FDA approval and launch of DESMODA, plus HEMANGEOL relaunch, expected to drive future growth

Outlook

Eton raises 2026 revenue guidance to exceed $120 mln, up from prior $110 mln forecast

Company expects full-year 2026 adjusted EBITDA margin of at least 30%

Eton expects full-year 2026 adjusted gross margin to exceed 70%

Result Drivers

PORTFOLIO GROWTH - Co said Q1 sales growth was driven by strong contributions from INCRELEX, ALKINDI SPRINKLE, GALZIN, Carglumic Acid, and addition of KHINDIVI

NEW PRODUCT LAUNCHES - FDA approval and launch of DESMODA and relaunch of HEMANGEOL expected to contribute significantly to revenue growth

Company press release: ID:nGNX6NdMSC

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
$0.05
Q1 Net Income
$1.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $35.00, about 13.6% above its May 13 closing price of $30.82

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)